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Galectin-1 (Gal-1)-binding to Gal-1 ligands on immune and endothelial cells can inﬂuence melanoma
development through dampening antitumor immune responses and promoting angiogenesis. However,
whether Gal-1 ligands are functionally expressed on melanoma cells to help control intrinsic malignant features
remains poorly understood. Here, we analyzed expression, identity, and function of Gal-1 ligands in melanoma
progression. Immunoﬂuorescent analysis of benign and malignant human melanocytic neoplasms revealed that
Gal-1 ligands were abundant in severely dysplastic nevi, as well as in primary and metastatic melanomas.
Biochemical assessments indicated that melanoma cell adhesion molecule (MCAM) was a major Gal-1 ligand on
melanoma cells that was largely dependent on its N-glycans. Other melanoma cell Gal-1 ligand activity conferred
by O-glycans was negatively regulated by α2,6 sialyltransferase ST6GalNAc2. In Gal-1-deﬁcient mice, MCAM-
silenced (MCAMKD) or ST6GalNAc2-overexpressing (ST6O/E) melanoma cells exhibited slower growth rates,
underscoring a key role for melanoma cell Gal-1 ligands and host Gal-1 in melanoma growth. Further analysis of
MCAMKD or ST6O/E melanoma cells in cell migration assays indicated that Gal-1 ligand–dependent melanoma
cell migration was severely inhibited. These ﬁndings provide a reﬁned perspective on Gal-1/melanoma cell
Gal-1 ligand interactions as contributors to melanoma malignancy.
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INTRODUCTION
Galectin-1 (Gal-1) is one of the 15 evolutionarily conserved
S-type lectins that bind lactosamine sugars on discrete cell
membrane proteins and extracellular matrix (ECM) compo-
nents (Cho and Cummings, 1995; Camby et al., 2006). Gal-1
is expressed by effector T and B cells, inﬂammatory
macrophages, decidual natural killer cells, FoxP3+ regulatory
T cells, and endothelial cells (ECs), where it has a key role in
suppressing innate and adaptive immune responses (Baum
et al., 1995; Rabinovich et al., 1998; Zuniga et al., 2001;
Koopman et al., 2003; Blois et al., 2007; Garin et al., 2007;
Kopcow et al., 2008; Thijssen et al., 2008; Ouyang et al.,
2011). Gal-1 is also elevated in certain tumor cells, where it
promotes tumor growth and cancer progression by immune
tolerizing effects on dendritic cells and effector T cells and by
angiogenesis via direct interactions with ECs (Rubinstein et al.,
2004; Thijssen et al., 2006, 2010; Demydenko and Berest,
2009; Ilarregui et al., 2009; Lefranc et al., 2011; Mathieu et al.,
2012; Cedeno-Laurent et al., 2012b,c; Laderach et al., 2013).
One recent report identiﬁed Gal-1 on mesenchymal stem cells
as a positive regulator of tumor growth (Szebeni et al., 2012).
Gal-1 elicits its effects via binding to glycoprotein (or
glycolipid) counter-receptor ligands that confer a Gal-1 ligand
activity and subsequent initiation of functional activities,
including adhesion/migration, immune suppression, and
angiogenesis. Our descriptions herein deﬁne a Gal-1 ligand
as a preferred membrane protein bearing poly-N-acetyllacto-
samine(s) on asparagine (N)- and/or serine/threonine (O)-
glycans in an optimal orientation for Gal-1-binding. Under-
standing how Gal-1 ligands regulate tumor growth could
provide important insights into the development of anticancer
therapeutics and lay the foundation for generation of reliable
diagnostic markers for tumor growth and metastasis.
Malignant melanoma is a well-documented tumor model
leveraging Gal-1/Gal-1 ligand interactions. Complete ablation
of melanoma- and host-derived Gal-1 expression severely
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limits melanoma growth (Rubinstein et al., 2004; Thijssen
et al., 2006; Toscano et al., 2007; Thijssen et al., 2010; Banh
et al., 2011; Cedeno-Laurent et al., 2012b). Gal-1 facilitates
melanoma immune evasion by reducing the number of IFN-γ-
producing T helper cells and cytolytic T cells, including
melanoma-speciﬁc cytolytic T cells (Rubinstein et al., 2004;
Toscano et al., 2007; Ilarregui et al., 2009; Cedeno-Laurent
et al., 2012b). Depending on local concentrations, Gal-1 can
engage dendritic cell/T-cell Gal-1 ligands CD7, CD43, and/or
CD45 and either initiate a proapoptotic activity or a
regulatory signaling circuit (Perillo et al., 1995; Pace et al.,
2000; Nguyen et al., 2001; Suzuki et al., 2005a; Hernandez
et al., 2006; Fulcher et al., 2009; Cedeno-Laurent et al., 2010,
2012a,b). Alternatively, melanoma- and host-derived Gal-1
bind ECs and support a number of proangiogenic activities,
including EC survival, migration, and capillary formation
in vitro and in vivo (Thijssen et al., 2006, 2008, 2010;
Mathieu et al., 2012; Szebeni et al., 2012; Laderach et al.,
2013; Croci et al., 2014). Gal-1-binding to CD146, otherwise
known as melanoma cell adhesion molecule (MCAM), on
ECs, in fact, can encourage survival (Jouve et al., 2013).
Although Gal-1/Gal-1 ligand interactions clearly promote
melanoma growth through immunosuppressive and
proangiogenic mechanisms, the direct impact of Gal-1 on
melanoma cells is not fully understood. One study shows that
Gal-1 on melanoma cells can mediate homotypic cell–cell
interactions, in part, via binding to Gal-1 ligand, 90K/
MAC-2BP (Tinari et al., 2001).
Here, we performed a comprehensive assessment into
expression, identity, and regulation of Gal-1 ligands on
melanoma cells and related malignant behavior. Dual
immunoﬂuorescence (IF) analysis of Gal-1 ligand expression
using an innovative Gal-1 probe showed that malignant
melanomas, including melanoma in situ, radial and vertical
growth phase melanomas, and melanoma metastases, con-
tained an abundance of Gal-1 ligand that was largely absent
on epidermal melanocytes in normal human skin, in benign
nevi, and in uninvolved skin adjacent to the malignant lesion.
Of note, dermal melanocytic nests in an atypical nevus with
spindle cell proliferation, inﬂammation, and features of
regression were also positive for Gal-1 ligands. Biochemical
analysis showed that MCAM, which, itself, has been
implicated in melanomagenesis (Xie et al., 1997; Jean et al.,
1998; Mills et al., 2002), was one of the major melanoma cell
Gal-1 ligands and was largely dependent on its N-glycans for
Gal-1-binding. We found that O-glycans, to a lesser extent,
also contributed to total melanoma cell Gal-1 ligand activity.
Gene expression analysis revealed that α2,6 sialyltransferase
ST6GalNAc2, whose α2,6 sialylation activity on a Core 1
O-glycan prevents synthesis of extended Core 2 O-glycans
that bind Gal-1 (Nguyen et al., 2001; Earl et al., 2010), was
signiﬁcantly downregulated in malignant melanoma cells
compared with human epidermal melanocytes (HEMs). When
MCAM-silenced (MCAMKD) or ST6GalNAc2-overexpressing
(ST6O/E) melanoma cells were grown in mice deﬁcient in Gal-
1, tumor growth was signiﬁcantly reduced. Similarly, Gal-1
ligand–dependent migration of MCAMKD or ST6O/E mela-
noma cells on ECM was inhibited, suggesting that Gal-1
ligand activity may be promoted by high MCAM and low
ST6GalNAc expression. Together, these data demonstrate a
key role for melanoma cell Gal-1 ligands, including MCAM,
and of Gal-1 ligand regulator, ST6GalNAc2, as functional
correlates with malignant behavior.
RESULTS
Expression of Gal-1 ligands is elevated in malignant melanomas
To investigate the relationship between Gal-1 ligand expres-
sion and malignant melanoma, we used dual IF to determine
Gal-1 ligand expression on benign and malignant melano-
cytes in human biological specimens. We stained for S100 (in
red), a marker of melanocyte-lineage cells, and Gal-1 ligands
with mouse Gal-1–human immunoglobulin chimera (Gal-
1hFc) (in green) or dmGal-1hFc (a nonbinding double mutant
control) as previously described (Cedeno-Laurent et al.,
2012b). Because S100 is also found in Langerhans cells, this
staining strategy was intentionally implemented to encompass
a predominant epidermal immune cell subset that could
potentially bear Gal-1 ligand.
We found that S100+ cells encompassing both Langerhans
cells and melanocytes in the epidermis of normal skin and a
benign nevus were negative for Gal-1 ligand expression
(Figure 1a and b). However, melanocyte-lineage cells in a
melanoma in situ were positive for both S100 and Gal-1
ligand (merged in yellow) (Figure 1c). Western blotting lysates
from normal HEMs and human melanoma G361 cells
(Figure 1d) and FACS staining of primary human metastatic
melanoma cells and human G361 melanoma cells (Figure 1e)
with Gal-1hFc revealed conspicuous elevation in Gal-1
ligand(s) on melanomas. Of note, detection of surface Gal-1
ligands was not signiﬁcantly masked by well-described
melanoma cell galectins, Gal-1, -3, and -9 (Braeuer et al.,
2012), as we did not stain appreciable levels of Gal-1, -3, and
-9 on the melanoma cell surface (Supplementary Figure S1
online). To verify Gal-1 ligand staining with statistical
signiﬁcance, IF analysis was performed on tissue microarrays
(containing 56 primary and 20 metastatic melanomas and 24
benign pigmented nevi) using Gal-1hFc (in green). In this
case, dual IF staining was not employed because of the
potential variations in S100 expression by metastatic mela-
noma cells (Aisner et al., 2005). Data demonstrated
signiﬁcantly higher mean intensities of Gal-1 ligand staining
on primary and metastatic melanomas compared with the
levels on benign nevi (Po0.001) (Figure 1f).
Additional dual IF staining of a premalignant nevus with
atypia and inﬂammation showed that dermal S100+ melano-
cytic nests were strongly positive for Gal-1 ligand, suggesting
that melanocyte localization to dermis may correspond with
Gal-1 ligand upregulation. Yet, dual IF staining of malignant
melanomas, including radial and vertical growth phase
subsets, showed that malignant melanocytic nests located in
the epidermis and dermis were strongly positive for Gal-1
ligand(s) (Figure 2b–d). Of note, epidermal melanocytes
outside of the tumor margin did not stain for Gal-1 ligand
(Figure 2b and c), highlighting the capacity of this method to
distinguish Gal-1 ligand+ malignant melanocytes from benign
epidermal counterparts.
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MCAM is a Gal-1 ligand on human melanoma cells
To identify potential Gal-1 ligands on melanoma cells, we
used protein G-afﬁnity chromatography and western blotting
to interrogate Gal-1-binding proteins in human melanoma
cells using Gal-1hFc as a probe (Cedeno-Laurent et al., 2010,
2012a). We detected major Gal-1-stained bands in the range
of 110–150 kDa as well as at 250 kDa in melanoma short-
term cultures and SK-MEL, SK-MEL2, and G361 melanoma
cell lines (Figures 1d and 3a). MCAM blotting was performed
in parallel to control for detection of a common melanoma-
speciﬁc marker (Figure 3a). Negative control blots probed
with secondary antibody alone, with Gal-1hFc and 50mM
lactose, or with dmGal-1hFc showed no staining, conﬁrming
carbohydrate dependence and Gal-1 ligand authenticity.
Protein G-afﬁnity chromatography of G361 melanoma cell
lysate with Gal-1hFc or dmGal-hFc control and tandem mass
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Figure 1. Galectin-1 (Gal-1) ligands are differentially expressed on normal human melanocytes and human melanoma cells. Dual immunoﬂuorescence (IF)
analysis of Gal-1 ligands with Gal-1hFc (in green) or dmGal1-hFc control and S100 with anti-S100A-B (in red) was performed on (a) formalin-ﬁxed, parafﬁn-
embedded (FFPE) sections of normal human skin (b), a benign junctional nevus, and (c) melanoma in situ. (d) Western blot analysis of Gal-1 ligands (with
Gal-1hFc), melanoma cell adhesion molecule (MCAM) polypeptide, SOX10, and β-actin in human epidermal melanocytes (HEMs) and G361 melanoma cell
lysates was performed. (e) Primary melanoma cells and G361 melanoma cells were FACS analyzed with Gal-1hFc or controls. (f) IF analysis of Gal-1 ligands was
performed on tissue microarrays (TMAs) containing primary (n= 56) and metastatic melanomas (n=20) and benign nevi (n=24). *Po0.001, statistical
signiﬁcance compared with benign nevi. Scale bars=100 μm.
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spectrometry analysis of corresponding eluates revealed
several potential Gal-1 ligand candidates. The candidate with
the highest number of peptide matches corresponding to a
membrane protein was MCAM (Figure 3b). Examination of the
entire list of protein matches indicated the presence of other
known human Gal-1 ligand(s), including, in descending order,
galectin-3-binding protein (90K/MAC-2BP), lysosomal-
associated membrane protein-1 and -2 (LAMP-1/2), and
carcinoembryonic antigen (Woynarowska et al., 1996; Tinari
et al., 2001) (Supplementary Figure S2 online). Validation of
MCAM as a Gal-1 ligand was ascertained by blotting Gal-1hFc
eluate from G361 cell lysates with anti-MCAM antibody.
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Vertical growth phase subset of primary malignant melanoma
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Figure 2. A premalignant melanocytic tumor and malignant melanomas are strongly positive for galectin-1 (Gal-1) ligands. Dual immunoﬂuorescence (IF)
analysis of Gal-1 ligands (in green) and CD8 or S100 (in red) was performed on formalin-ﬁxed, parafﬁn-embedded (FFPE) sections of (a) a combined atypical
nevus and an atypical spindle cell proliferation with inﬂammation (asterisks indicate Gal-1 ligand+ CD8+ cells and arrows indicate Gal-1 ligand+ S100+ dermal
nests). Dual IF staining of (b) primary cutaneous melanomas, including (c) radial and (d) vertical growth phase subsets, was also performed. Brackets in b (upper
panel) and c (lower panel) indicate margin tissue where nonmalignant epidermal S100+ cells were Gal-1 ligand−. H&E, hematoxylin and eosin. Scale
bars=100 μm and photomicrographs enlarged in the lower panels as indicated.
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Eluates from nonbinding dmGal-1hFc control and from Gal-
1hFc-afﬁnity chromatography of Gal-1 ligand+ human acti-
vated T-cell lysate were examined in parallel to control for
Gal-1 speciﬁcity. In Figure 3c, a known human T-cell Gal-1
ligand, CD45RO, was puriﬁed in Gal-1hFc-eluate, whereas
MCAM was isolated from G361 cell lysate. On the other hand,
dmGal-1hFc did not purify CD45RO or MCAM, showing
dependence on functional Gal-1 (Figure 3c). We additionally
immunoprecipitated 90K/MAC-2BP from human A375 mela-
noma cells and blotted with Gal-1hFc to demonstrate that Gal-
1hFc could recognize a human Gal-1 ligand previously
identiﬁed on A375 cells using human Gal-1 (Supplementary
Figure S3 online) (Iacobelli et al., 1986; Tinari et al., 2001).
To solidify MCAM as a Gal-1 ligand, western blotting anti-
MCAM immunoprecipitates of G361 (Figure 4a) or primary
melanoma (Figure 4b) cell lysates with Gal-1hFc was also
performed and demonstrated that MCAM indeed binds Gal-1.
Anti-MCAM immunoprecipitates from A375 cells were
blotted with Gal-1hFc, demonstrating that Gal-1-binding
glycans were similarly displayed on MCAM (Figure 4c).
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Figure 3. Afﬁnity puriﬁcation of candidate galectin-1 (Gal-1) ligands from human melanoma cells implicates melanoma cell adhesion molecule (MCAM)
as a major Gal-1 ligand. (a) Primary metastatic melanoma (mel) cells or melanoma cell line lysates were blotted with Gal-1hFc or control anti-MCAM. As shown
in (b), the top 10 proteins and corresponding number of peptide matches identiﬁed by tandem mass spectrometry (MS/MS) of elutes from protein G afﬁnity
chromatography with Gal-1hFc or negative control dmGal-1hFc and G361 cell lysate are listed. (c) Control activated human T-cell or melanoma G361 cell lysate
and eluates from protein G afﬁnity chromatography with Gal-1hFc or negative control dmGal-1hFc were blotted with anti-CD45RO or anti-MCAM. Arrows
indicate the presence of T-cell CD45RO at 190 kDa and melanoma cell MCAM at 120 kD.
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(Figure 4a and c). Control immunoprecipitates with either
anti-MCAM or anti-CD45RO in the absence of lysate revealed
nonspeciﬁc stained Ig bands at 100 and 150 kDa (Figure 4c).
As expected, anti-CD45RO immunoprecipitate from human
T cells was blotted with Gal-1hFc, conﬁrming capacity of Gal-
1hFc to authenticate a hallmark human Gal-1 ligand
(Figure 4c) (Cedeno-Laurent et al., 2012a). In all, afﬁnity
chromatography, western blotting, and immunoprecipitation
approaches helped identify MCAM as a putative Gal-1 ligand.
As MCAM has eight potential N-glycosylation sites
(Lehmann et al., 1989), we examined whether MCAM Gal-
1-binding determinants resided on N-linked glycans. We
treated anti-MCAM immunoprecipitates with PNGase, sepa-
rated products by SDS-PAGE, and blotted with Gal-1hFc or
controls to detect Gal-1-binding MCAM. PNGase-treated anti-
MCAM immunoprecipitates were also blotted with anti-
MCAM to control for MCAM detection. PNGase treatment
lowered MCAM size to ~ 85 kDa, indicative of de-N-
glycosylation, and eliminated its Gal-1-binding activity
(Figure 4d). To determine the relative contribution of MCAM
Gal-1 ligand activity, we analyzed Gal-1 ligand expression in
A375 and G361 melanoma cells knocked down (KD) for
MCAM expression. Using western blot and FACS analysis, we
showed a signiﬁcant reduction in MCAM expression by 90%
(Po0.001; Figure 4e) and, compared with Scr controls,
MCAMKD cell variants exhibited a 40% reduction in Gal-1
ligand activity (Figure 4f). Furthermore, dependency of
MCAM for binding human Gal-1 was validated by FACS
analysis and conﬁrmed the capacity of our Gal-1hFc
formulation to similarly detect human Gal-1 ligands
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(a) Anti-MCAM immunoprecipitates from G361 or (b) primary melanoma cell lysates were blotted with Gal-1hFc or anti-MCAM. IP, immunoprecipitation.
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All experiments were performed three times.
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(Supplementary Figure S4 online) (Tsai et al., 2008). Control
treatments containing 50mM lactose or probing with dmGal-
1hFc did not detect any measurable Gal-1 ligand. These data
suggested that MCAM through its N-glycosylations was a
major Gal-1 ligand on melanoma cells.
α2,6 sialyltransferase ST6GalNAc2 is a negative regulator of
Gal-1 ligand activity in melanoma cells
As MCAM silencing on melanoma cells did not completely
lower Gal-1 ligand activity, we subsequently ascertained
whether other glycoconjugates could contribute to total
cellular ligand activity. Bromelain protease treatment before
assaying for Gal-1 ligand activity on A375 and G361
melanoma cells indicated that nearly all of the cellular
activity was contributed by glycoproteins with a negligible
contribution by glycolipids (Supplementary Figure S5a
online). Hence, we then treated melanoma cells with an
effective complex N-glycan inhibitor, kifunensine, and found
that Gal-1 ligand activity was signiﬁcantly reduced by 80 and
50% in A375 and G361 cells, respectively (Po0.001;
Figure 5a). This suggested that any residual activity above
the protease treatment level was likely due to O-glycans. In a
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control experiment, binding of phytohemagglutinin, which
binds tetra-antennae of complex N-glycans, was completely
eliminated, validating N-glycan removal (Supplementary
Figure S5b online). We next examined whether the mem-
brane protein LAMP-1 identiﬁed by Gal-1 afﬁnity
chromatography and bearer of putative O-glycan sites could
also serve as a Gal-1 ligand. We observed that LAMP-1
immunoprecipitates from melanoma cell avidly bound Gal-1
(Supplementary Figure S6 online). These data suggested that
LAMP-1, which has been shown to display O-glycans and
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Figure 6. In vivo growth of melanoma cells and migration of melanoma cells on Matrigel are regulated, in part, by host galectin-1 (Gal-1) and on melanoma
cell Gal-1 ligands. (a) Wild-type (WT) or Gal-1− /− mice were inoculated subcutaneously (s.c.) with control, ST6O/E, or MCAMKD B16 cells and monitored for
tumor growth. Mean tumor volumes (SEM) (n= 8/group) were calculated and plotted against time. (b–e) Control, ST6O/E, or MCAMKD A375 and B16 melanoma
cells preblocked with Gal-1hFc, hFc, or lactose were assayed for formation of tube-like structures on Matrigel. Tube-like structures were illustrated in
representative phase photomicrographs (scale bars=100 μm). The number of tube-like structures was expressed as % Control hFc-treated cells. *Po0.05,
**Po0.01, and ***Po0.001, statistical signiﬁcance compared with hFc-control cells. Data were collected from at least three experiments.
EM Yazawa et al.
MCAM and ST6GalNAc2 Regulate Melanoma Cell Gal-1 Ligand Activity
1856 Journal of Investigative Dermatology (2015), Volume 135
bind Gal-1 (Skrincosky et al., 1993; Ohannesian et al., 1994),
could contribute to melanoma cell Gal-1 ligand activity.
Recent data suggest that high expression of α2,6 sialyl-
transferase ST6GalNAc2, which transfers sialic acid in a α2,6
linkage to N-acetylgalactosamine on Core 1 O-glycans
(Marcos et al., 2004), prevents Gal-3-binding to unmodiﬁed
Core 1 O-glycan (Murugaesu et al., 2014). As Gal-1 binds
extended Core 2 O-glycans, we investigated whether ST6Gal-
NAc2 could neutralize O-glycan-dependent Gal-1 ligand
activity. We hypothesized that ST6GalNAc2 was differentially
expressed between Gal-1 ligand− HEM cells and Gal-1
ligand+ melanoma cells. Real-time quantitative reverse-tran-
scriptase–qPCR analysis revealed that, compared with expres-
sion in HEMs, ST6GalNAc2 was downregulated in A375 and
G361 cells by 65- and 30-fold, respectively (Figure 5b). In fact,
ST6GalNAc2 was uniformly downregulated in 13 melanoma
cell lines (Figure 5c). To examine the negative role of
ST6GalNAc2 in Gal-1 ligand activity, we generated G361
and A375 cells, along with B16 melanoma cells stably
overexpressing ST6GalNAc2 and assayed for Gal-1 ligand
activity. ST6GalNAc2-overexpressing (ST6O/E) cell variants
exhibited ~30% lower Gal-1 ligand activity compared with
vector control cells (Po0.01; Figure 5d). Assaying for binding
of Lycopersicon esculentum lectin, which binds poly-N-
acetyllactosamines known for binding Gal-1 (Skrincosky
et al., 1993; Ohannesian et al., 1994; Nguyen et al., 2001;
Earl et al., 2010), further showed that ST6O/E cell variants
expressed reduced levels of poly-N-acetyllactosamines
(Figure 5e). These data suggested that ST6GalNAc2 could
potentially serve as a negative regulator of Gal-1-binding to
O-glycans (Figure 5f).
Melanoma cell Gal-1 ligands contribute to tumor formation in
mice
To investigate whether Gal-1 collaborates with MCAM or
other Gal-1 ligands regulated by ST6GalNAc2 to trigger
melanoma growth, we assayed the growth of MCAM-silenced
(MCAMKD) (Supplementary Figure S7 online) or ST6O/E B16
melanoma cells in mice deﬁcient in Gal-1. To rule out
intrinsic alterations in proliferation due to silencing/over-
expression methods, we compared MCAMKD or ST6O/E B16
cell proliferation with vector controls in a carboxyﬂuorescein
succinimidyl ester dilution assay and found no differences in
proliferation rates (Supplementary Figure S8 online). Assess-
ments on longitudinal growth of control, MCAMKD, and
ST6O/E B16 cells in wild-type mice showed that MCAMKD
tumors grew at similar rates as control cells, whereas ST6O/E
tumors exhibited slower growth (Po0.01; Figure 6a). Prior
data, in fact, show that melanoma cells expressing variable
levels of MCAM grow at similar rates in mice (Wu et al.,
2008), and this may be associated with the pleiotropic role
of MCAM in cancer development (Wang and Yan, 2013).
However, as expected, MCAMKD or ST6O/E tumors when
inoculated in Gal-1− /− mice grew at signiﬁcantly slower
velocities (Po0.001; Figure 6a). These data suggested that
collaboration of host-derived Gal-1 and melanoma cell Gal-1
ligands, governed by either MCAM or ST6GalNAc2 expres-
sion, was necessary for optimal melanoma growth.
To further investigate MCAM and ST6GalNAc2 in malig-
nant potential of melanoma cells, we examined the ability of
MCAMKD and ST6O/E melanoma cells to migrate in a well-
described Matrigel assay (Frank et al., 2011). As the ECM used
is rich in Gal-1 (Croci et al., 2012) (Supplementary Figure S9
online), we were able to assay MCAMKD or ST6O/E melanoma
cell migration in a Gal-1 ligand–dependent manner. Although
Gal-3 and Gal-9 ligands could also potentially bind Gal-1,
requirement for melanoma cell Gal-1 ligands was established
by preincubating and growing cells in the presence of Gal-
1hFc (or hFc control) to bind ligand and interfere with native
Gal-1-binding in the Matrigel. Moreover, Gal-1 dependence
and galectins in general were substantiated by adding lactose
in the assay buffer and in the ECM preparation. Although
migration of control A375 and B16 cells treated with hFc was
observed, preincubation with Gal-1hFc signiﬁcantly reduced
migratory activity (Figure 6b–e). To our surprise, MCAMKD
A375 cell migratory activity was severely blunted even in the
absence of Gal-1hFc, implicating additional non-Gal-1-
binding functions (Figure 6b and c; Po0.001). MCAMKD
B16 cells also exhibited blunted migratory activity when
compared with control cells (Po0.001), but migration was
further reduced in the presence of Gal-1hFc (Po0.01; Figure
6d and e). ST6O/E A375 and ST6O/E B16 cell migration was
also attenuated compared with control cells and was further
inhibited by Gal-1hFc pretreatment (Po0.01). These results
suggested that melanoma cell Gal-1 ligands and Gal-1 in
ECM were important, in part, for effective migration that
mirrored data on the role of Gal-1 in ovarian tumor cell
adhesion to ECM (Skrincosky et al., 1993).
DISCUSSION
Studies from a number of laboratories show that Gal-1,
whether distributed from tumor cells or the host, is critical for
melanoma growth. Gal-1 can suppress effector T-cell function
and antitumor immunity (Ilarregui et al., 2009; Banh et al.,
2011), as well as trigger proangiogenic activity in melanomas
(Thijssen et al., 2006, 2008, 2010). There are corresponding
binding activities between Gal-1 and its counter-receptor
glycoprotein ligand(s) to convey these protumorigenic proper-
ties. As demonstrated on immune cells and ECs, Gal-1
ligands commonly display poly-N-acetyllactosamines on their
N- and/or O-glycans. CD7, CD43, CD45, CD146, and
vascular endothelial growth factor receptor 1, for example,
are well-described T-cell, dendritic cell, or EC Gal-1 ligands
that, upon Gal-1-binding, transmit signals that help induce
immunoregulatory, proapoptotic, prosurvival, or proangio-
genic activities (Hernandez et al., 2006; Fulcher et al., 2009;
Cedeno-Laurent et al., 2010, 2012a,c; Jouve et al., 2013;
Croci et al., 2014; Suzuki et al., 2005a,b). Interestingly,
analysis of melanoma cell Gal-1 ligands and their glycosyl-
transferase regulator(s) and relationship to melanoma malig-
nancy has not been formally addressed.
Here, we studied the expression, identity, and regulation of
Gal-1 ligands on melanoma cells. Our data implicate
melanoma Gal-1 ligands, notably N-glycosylated MCAM,
and Gal-1-binding O-glycans negatively regulated by α2,6
sialyltransferase ST6GalNAc2 as protumorigenic factors on
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melanoma cells. Prior data, in fact, show that MCAM
expression directly correlates with melanoma metastasis
(Luca et al., 1993; Xie et al., 1997; Mills et al., 2002; Kim
et al., 2012) and ST6GalNAc2 also acts as a negative
regulator of breast cancer metastasis by forming non-Gal-3-
binding sialylated Core 1 O-glycans (Murugaesu et al., 2014).
Our ﬁndings further highlight MCAM as a Gal-1 ligand and
ST6GalNAc2 as a regulator of Gal-1 ligand activity in the
glyco-pathogenesis of melanoma growth.
Using Gal-1hFc chimera, we probed Gal-1 ligands on
melanoma cells by IF, ﬂow cytometry, and western blotting.
Although the glycan-binding repertoire of Gal-1hFc is not
identical to human Gal-1 (Cedeno-Laurent et al., 2010), Gal-
1hFc upholds hallmark N-acetyllactosamine-binding activity
and binds the same glycoproteins as human Gal-1 as shown
here and elsewhere (Cedeno-Laurent et al., 2010, 2012a,b;
Barthel et al., 2011). Although a potential limitation of this
study, Gal-1hFc can interrogate human Gal-1 ligands without
the need for structure stabilizers. Although efforts using native
Gal-1 do exist (Kaltner et al., 1997; Andre et al., 1999; Plzak
et al., 2000), native human Gal-1 is problematic for the use in
bioassays due to rapid oxidative deactivation and the need for
reducing chemicals, complicating interpretation of ligand-
binding data. Previous studies using alkylation-induced
stabilization or cysteine-less Gal-1 mutants illustrate other
methods used to circumvent drawbacks of probing with
native Gal-1 (Powell and Whitney, 1984; Inagaki et al., 2000;
Nishi et al., 2008; Stowell et al., 2009).
Our initial assessments focused on whether Gal-1 ligands
were differentially expressed on melanocytes in normal
human skin and in human benign and malignant melanocytic
specimens. While routinely detecting Gal-1 ligands on
melanoma cells, including metastases, radial and vertical
growth phase subsets, and melanoma in situ, we did not
observe a similar high level of Gal-1 ligand staining on S100+
cells in the epidermis of normal skin or adjacent uninvolved
skin in melanoma lesions. As normal melanocytes are part of
the S100+ cell population in the skin, these data indicated that
normal melanocytes expressed low levels of Gal-1 ligand. The
lack of Gal-1 ligand detection in HEM cell lysates supported
this notion. We did, however, detect dermal nests of Gal-1
ligand+ S100+ cells in a premalignant atypical nevus lesion,
suggesting that Gal-1 ligand expression may correspond with
transition to malignancy. Further IF studies on other pre-
malignant lesions, including melanoma mimics, are needed
to strengthen the speculation that Gal-1 ligands are biomar-
kers of malignancy.
By performing Gal-1-afﬁnity chromatography and mass
spectrometry of protein isolates, we were able to identify that
MCAM was a major ligand on melanoma cells. LAMP-1 and
-2 and carcinoembryonic antigen were also identiﬁed,
although they were relatively less abundant. Analysis of
Gal-1 ligand activity on MCAMKD melanoma cells revealed
that MCAM, indeed, contributed to a signiﬁcant portion (35%)
of total cellular ligand activity. Furthermore, Gal-1 weak
binding to de-N-glycosylated MCAM demonstrated that
MCAM Gal-1 ligand activity was largely dependent on its
N-glycans.
As de-N-glycosylation and protease treatment data sug-
gested that a residual Gal-1-binding activity was expressed on
melanoma cells, we explored the potential contribution of
O-glycans. Given that α2,6 sialyltransferase ST6GalNAc2 can
prevent Core 2 O-glycan formation (Marcos et al., 2004) and
related Gal-1-binding Core 2 structures (Nguyen et al., 2001;
Earl et al., 2010), we ﬁrst examined whether ST6GalNAc2
was differentially expressed in Gal-1 ligandlo HEM and Gal-1
ligandhi melanoma cells. We observed consistent down-
regulation of ST6GalNAc2 in Gal-1 ligandhi melanoma cells
compared with HEMs, implicating its potential role in
blocking Gal-1 ligand activity conferred by O-glycans (as
illustrated in Figure 5f). This notion was solidiﬁed by assaying
for Gal-1 ligand expression and L. esculentum binding in
ST6O/E A375, G361, and/or B16 cells, whose Gal-1 ligand
activity and Lycopersicon esculentum lectin binding were
lowered, implicating other non-MCAM O-glycan-bearing
proteins, such as LAMP-1, as constituents of cellular ligand
activity (Carlsson et al., 1993; Ohannesian et al., 1994).
In vivo data using MCAMKD and ST6O/E melanoma cells
suggested that MCAM functioned as a protumorigenic factor
and ST6GalNAc2 served as a negative tumorigenic regulator
in collaboration with host Gal-1. Although Gal-1 produced by
melanoma cells has a role in immunoregulation and
angiogenesis (Rubinstein et al., 2004; Thijssen et al., 2006,
2010; Cedeno-Laurent et al., 2012b,c), in vivo results shown
here indicated that host Gal-1 was critical for MCAM- and
ST6GalNAc2-dependent tumor growth. Growth of MCAMKD
or ST6O/E melanoma cells in wild-type mice suggested that
melanoma-derived Gal-1 was incapable of fully compensat-
ing for the lack of host Gal-1. In fact, our MCAMKD
tumorigenicity data in wild-type mice paralleled prior work
(Wu et al., 2008) and strengthened our contention that, when
binding partner Gal-1 is deﬁcient in mice, can dependency
on MCAM Gal-1 ligand activity for robust melanoma growth
be appreciated.
In migration assays, Gal-1 ligand neutralization and lactose
treatments supported the concept that melanoma Gal-1
ligands helped confer migratory activity. Hence, evaluations
on the relative migratory activity of MCAMKD and ST6O/E
melanoma cells indicated that MCAM expression and
ST6GalNAc2 downregulation were critical for optimal Gal-1
ligand–mediated migratory activity. Because MCAM deﬁ-
ciency abrogated migration below Gal-1 ligand neutralization
of control cells, we speculate that additional non-Gal-1 effects
could have been affected by MCAM deﬁciency. Indeed,
MCAM has been shown to affect cell morphogenesis (Zeng
et al., 2012) or the function of vascular endothelial growth
factor receptor (Jiang et al., 2012) that is required for optimal
migration in this assay system (Frank et al., 2011). Of note,
Gal-1hFc-binding of melanoma cell Gal-1 ligands in solution
did not, itself, promote migration, suggesting that Gal-1
immobilized within ECM may be more efﬁcient at forming
lattices and triggering a migratory activity on melanoma cells.
Further studies are underway to dissect Gal-1-dependent
signaling in melanoma cells through MCAM and other Gal-1
ligands.
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In summary, observations herein advance the hypothesis
that Gal-1/Gal-1 ligand axis is critical for melanoma devel-
opment, while providing ﬁrm insights into the intrinsic role of
Gal-1 ligands on melanoma cells. Our data now implicate the
inﬂuence of Gal-1 on the malignant behavior of melanoma
cells through engagement of its Gal-1 ligands. Results now
raise the possibility that malignant progression is controlled
by expression of Gal-1 ligands, such as MCAM among other
membrane glycoproteins, and partially by negative regulator,
ST6GalNAc2. These ﬁndings have invigorated further inquiry
on the glyco-molecular transition of normal and premalignant
melanocytes to malignant melanocytes and whether Gal-1
ligand expression can help discriminate malignant melanoma
from tumor mimics. This report expands our perspective on
the glyco-pathogenesis of malignant melanoma and strength-
ens the use of Gal-1 antagonists, such as neutralizing
antibodies, as therapeutically efﬁcacious reagents to treat
malignant melanoma.
MATERIALS AND METHODS
Cells
Please see Supplementary Materials and Methods section online for
extensive list of human and mouse cells, methods of cell acquisition,
validation of authenticity, and institutional approvals.
Immunoﬂuorescence
Archival formalin-ﬁxed, parafﬁn-embedded normal human skin,
benign melanocytic tumors, and malignant melanoma specimens
were obtained in accordance with the approval of Institutional
Review Board, stained with hematoxylin and eosin, and analyzed by
IF. Studies consisted of tissues from human normal skin (n= 3),
benign nevi (n= 3), a combined atypical nevus and atypical spindle
cell proliferation with inﬂammation, a malignant melanoma in situ,
and primary malignant melanomas (n= 5). In addition, tissue
microarray sections containing 56 primary melanomas, 20 metastatic
melanomas, and 24 benign pigmented lesions were obtained
commercially (BioMax, Rockville, MD). Following deparafﬁnization
and antigen retrieval using EDTA (pH 8), sections were treated with
hydrogen peroxide for 5 minutes, protein block for 30 minutes, and
then dual stained with rabbit polyclonal anti-S100 (clone Z0311;
1:400; Dako, Carpinteria, CA) or rabbit IgG anti-human CD8
(1:2,000; Abcam, San Francisco, CA) and/or Gal-1hFc or dmGal-
1hFc (each at 50 μgml− 1) for 1 hour at room temperature as
previously described (Cedeno-Laurent et al., 2010, 2012b). Slides
were incubated for 30 minutes with a cocktail of Cy-3 anti-rabbit IgG
(1:500) (Invitrogen) and with allophycocyanin goat Fab anti-hFc
(1:500) (Jackson ImmunoResearch, West Grove, PA) and counter-
stained with 4',6-diamidino-2-phenylindole. Slides were treated with
ProLong Gold Anti-Fade (Invitrogen, Carlsbad, CA) before ﬂuores-
cence microscopy. Staining was analyzed with a BX51/BX52
microscope and images were acquired using a Nikon eclipse Ti
microscope and a Nikon FDX-35 digital camera (Nikon, Tokyo,
Japan) and analyzed using CytoVision 3.6 software (Applied Imaging,
San Jose, CA).
Fluorescence analysis of tissue microarray–stained slides was
performed using Spot Advanced software (Sterling Heights, MI).
Representative core ﬁelds at × 10 magniﬁcation (encompassing
485% of each core) were analyzed using semiquantitative raw
intensity analysis with NIH Image J software (http://imagej.nih.gov/ij).
Please see Supplementary Materials and Methods section online for
detailed description of immunoﬂuorescence procedures, type and
number of analyzed tissues, and method of quantiﬁcation.
Lectin-afﬁnity chromatographic, mass spectrometry, and
western blot analysis
Protein G-afﬁnity chromatography of Gal-1 ligands was performed
on human G361 melanoma or control human activated T-cell lysates
using Gal-1hFc or nonbinding dmGal-1hFc probes (Cedeno-Laurent
et al., 2010) incubated in a ratio of 100 μg lysate/2 μg for 18 hours at
4 °C. Eluates were washed extensively in lysis buffer containing 2%
NP-40 and in phosphate-buffered saline. For Gal-1 ligand identiﬁca-
tion, eluates from Gal-1hFc- or dmGal-1hFc–protein G chromato-
graphy of G361 lysates were analyzed by tandem mass spectrometry
by the Beth-Israel Deaconess Medical Center Mass Spectrometry
Core Facility (Boston, MA).
For western blot analyses, whole-cell lysates, Matrigel, eluates
from dmGal-1hFc/Gal-1hFc/protein G chromatography and immu-
noprecipitates using anti-MCAM (clone P1H12; Lifespan Bios-
ciences, Seattle, WA), anti-MCAM (EPR3208; EMD Millipore,
Billerica, MA), anti-CD45RO (UCH-L1; Santa Cruz Biotechnology,
Dallas, TX), anti-LAMP-1 (clone H4A3; BioLegend, San Diego, CA),
anti-90K/MAC-2BP (clone SP-2; a generous gift from Dr Stefano
Iacobelli, MediaPharma Srl, Chieti, Italy) (Iacobelli et al., 1986), or
isotype control antibody were prepared, separated on reducing 4–
20% SDS-PAGE gradient gels (Bio-Rad, Hercules, CA), and
transferred to immunoblot polyvinylidene diﬂuoride membrane
(Bio-Rad) as previously described (Cedeno-Laurent et al., 2012a).
Where indicated, anti-MCAM immunoprecipitates were treated with
Peptide-N-Glycosidase F (PNGase) as per the manufacturer’s
protocol (New England Biolabs, Ipswich, MA). MCAM, CD45RO,
Gal-1 ligands, SOX10, Gal-1, and LAMP-1, MAC-2BP, and β-actin
were western blotted with anti-MCAM (P1H12 or EPR3208; 1
μg ml−1), anti-CD45RO (UCH-L1; 1 μgml− 1), Gal-1hFc (10 μg-
ml− 1), nonbinding mutant dmGal-1hFc (10 μgml− 1), goat poly-
clonal anti-SOX10 (Santa Cruz Biotechnology) (1 μgml− 1), goat
polyclonal anti-mouse/human Gal-1 (2 μgml− 1; R&D Systems,
Minneapolis, MN), anti-LAMP-1 (H4A3), anti-90k/MAC-2BP (clone
SP-2), or anti-β-actin (1 μgml− 1; BD Biosciences, San Jose, CA),
respectively, then incubated with relevant alkaline phosphatase–
conjugated secondary antibody (Jackson ImmunoResearch) and
developed with Western Blue alkaline phosphatase substrate
(Promega, Madison, WI) as previously described (Cedeno-Laurent
et al., 2010). Alternatively, blots were incubated with IRDye-800CW
anti-hIgG, IRDye-800CW anti-rabbit IgG, or IRDye-680RD anti-
mouse IgG and analyzed on a LI-COR Odyssey Imaging System (LI-
COR Biosciences, Lincoln, NE).
Real-time quantitative reverse-transcriptase–PCR analysis of
galectins
Please see Supplementary Materials and Methods section online for
detailed procedures on real-time quantitative reverse-transcriptase–
PCR.
Silencing of MCAM
Please see Supplementary Materials and Methods section online for
detailed procedures on stable MCAM silencing in cells.
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Overexpression of ST6GalNAc2
Please see Supplementary Materials and Methods section online for
detailed procedures on stable ST6GalNAc2 overexpression in cells.
Flow cytometry
Please see Supplementary Materials and Methods section online for
detailed procedures on FACS analysis and glyco-metabolic inhibitor
treatments.
Melanoma cell migration assay
Melanoma cells were plated and cultured on Matrigel, an ECM
preparation from a mouse sarcoma and a rich source of Gal-1 (Croci
et al., 2012) as previously described (Frank et al., 2011). The presence
of Gal-1 in Matrigel preparations was validated by western blot
analysis (Supplementary Figure S9 online). Negative controls con-
sisted of adding 50mM lactose to Matrigel and assay medium or
pretreating melanoma cells with saturating levels of Gal-1hFc
(Cedeno-Laurent et al., 2010).
Before assays, melanoma cells were cultured for 24 hours in
RPMI-1640/10% fetal bovine serum/1% penicillin/streptomycin with
50mM lactose to elute prebound melanoma-derived Gal-1, inhibit
melanoma cell Gal-1 ligand engagement, and silence Gal-1 ligand–
dependent cellular events. Cells were then harvested with 1mM EDTA,
washed 3× in phosphate-buffered saline, suspended in RPMI-1640-
/10% fetal bovine serum/100 ngml−1 recombinant human or
recombinant mouse VEGF (R&D Systems), and seeded at 2×104/well
in 24-well plates coated with growth factor–depleted Matrigel
(BD Biosciences). Where indicated, Gal-1hFc, hFc control, or 50mM
lactose control was added to occupy and competitively inhibit
melanoma cell Gal-1 ligand binding to native Gal-1 in Matrigel. Tube-
like cellular formation, which corresponds with melanoma virulence
(Frank et al., 2011), was examined by phase-contrast microscopy after
72 hours. Tube-like formations deﬁned as ≥2 cells forming elongated
structures were counted at 10× magniﬁcation from 4 different ﬁelds
for each condition. Experiments were conducted at least 3 times.
In vitro melanoma cell proliferation assay
Please see Supplementary Materials and Methods section online for
detailed procedures on the melanoma cell proliferation assay.
Melanoma growth in mice
Scr or vector control, MCAMKD, or ST6O/E B16 melanoma cells
(1× 105) were inoculated subcutaneously in the left ﬂank of wild-
type or Gal-1− /− C57BL/6 mice (The Jackson Laboratory, Bar
Harbor, ME). Tumor growth (n= 8/experiment) was measured every
other day using calipers. All animal experiments were authorized by
the institutional animal care and use committee, and mice were
killed as per their guidelines. Experiments were repeated 3 times.
Statistical analysis
Statistical signiﬁcant comparisons were ascertained by two-tailed
Student’s t-test, a paired t-test, one-way analysis of variance with
Dunnett’s post test, or contingency table on GraphPad Prism
(GraphPad Software, La Jolla, CA).
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